Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: shinno y. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Yamamoto N, Ohe Y. Shibaki R, et al. Among authors: shinno y. Cancer Immunol Immunother. 2020 Jul;69(7):1229-1236. doi: 10.1007/s00262-020-02539-2. Epub 2020 Mar 10. Cancer Immunol Immunother. 2020. PMID: 32152703 Free PMC article.
Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M, Yoshida T, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: shinno y. Eur J Cancer. 2020 Nov;140:28-36. doi: 10.1016/j.ejca.2020.08.028. Epub 2020 Oct 8. Eur J Cancer. 2020. PMID: 33039811
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
Shirasawa M, Yoshida T, Horinouchi H, Kitano S, Arakawa S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Kanda S, Watanabe R, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: shinno y. Br J Cancer. 2021 Mar;124(5):925-932. doi: 10.1038/s41416-020-01188-7. Epub 2020 Nov 30. Br J Cancer. 2021. PMID: 33250511 Free PMC article.
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: shinno y. Clin Lung Cancer. 2021 Jul;22(4):282-291.e6. doi: 10.1016/j.cllc.2021.02.003. Epub 2021 Feb 8. Clin Lung Cancer. 2021. PMID: 33722498
Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y. Takeyasu Y, et al. Among authors: shinno y. Jpn J Clin Oncol. 2021 Jul 1;51(7):1114-1122. doi: 10.1093/jjco/hyab059. Jpn J Clin Oncol. 2021. PMID: 33881137
Corrigendum to: Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y. Takeyasu Y, et al. Among authors: shinno y. Jpn J Clin Oncol. 2021 Jul 1;51(7):1183. doi: 10.1093/jjco/hyab092. Jpn J Clin Oncol. 2021. PMID: 34100088 No abstract available.
130 results